MRNA insider ownership: who sold, why, and what they still hold

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
James Mock Chief Financial Officer	704	$190.01	1.2%	60K	Oct 5, 2026	Oct 7, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Stephen Hoge President	40,281	$146.07	2.3%	1.72M	Sep 15, 2026	Sep 16, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Stephen Hoge President	40,294	$144.13	2.3%	1.68M	Sep 14, 2026	Sep 16, 2026

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
James Mock Chief Financial Officer	34,836	$134.49	37%	59K	Sep 10, 2026	Sep 14, 2026

What stands out

Three insiders sold shares but ended with larger stakes, because more shares came in than were sold: Stephane Bancel (sold 499K, 2.4% of starting holdings; 1.45M added), Stephen Hoge (sold 401K, 25% of starting holdings; 543K added) and Noubar Afeyan (sold 9.3K, 0.4% of starting holdings; 13K added).Stephane Bancel: largest sale, Aug 5, 2026 · Stephen Hoge: largest sale, Feb 23, 2026 · Noubar Afeyan: largest sale, May 21, 2026

Selling rose in the last 90 days but the year remains well below the 5-year average: officers and directors sold 671K shares, against an average of 98K per 90 days earlier in the period. Most of it was Stephane Bancel (499K shares in the last 90 days, 2.3% of holdings) and Stephen Hoge (134K shares in the last 90 days, 8.3% of holdings); 100% of these sales were under disclosed plans.Stephane Bancel: largest recent sale, Aug 5, 2026 · Stephen Hoge: largest recent sale, Sep 15, 2026

Percentages cover 10 of 15 officers and directors. 5 are left out

Left out: Shannon Klinger, James Mock and Abbas Hussain (most of their shares vested during the period, so a percentage would mislead); Soria Banque and Michael McDonnell (held no vested shares at the start).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is the insider's vested stake at the start of the period (Oct 8, 2025). The gold part is what they sold.

SoldRest of starting stakeAdded during the period

Stephane Bancel

Chief Executive Officer, Director

Sold 2.4%, but 1.44M shares were added (mostly vesting), so the stake grew

2.4% · $28.7MDisclosed plan

Stephen Hoge

President

Sold 25%, but 538K shares were added (mostly vesting), so the stake grew

25% · $28.4MDisclosed plan

James Mock

Chief Financial Officer

Sold 37% of the shares held or received (after tax withholding) during the period†. No bar against the starting stake: most of these shares arrived during the period.

$4.7MDisclosed plan

Shannon Klinger

Chief Legal Officer

Sold 20% of the shares held or received (after tax withholding) during the period†. No bar against the starting stake: most of these shares arrived during the period.

$1.4MDisclosed plan

Noubar Afeyan

Director

Sold 0.4%, but 9.3K shares were added (mostly vesting), so the stake grew

0.4% · $434KNo plan disclosed

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosed

Outside holders, reported separately

Noubar Afeyan (for the outside shareholder represented on the board) sold $703K in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Moderna CEO selling stock?

Yes. Stephane Bancel sold 499K shares ($28.7M, 2.4% of starting holdings) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Moderna insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 99% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 0.7% had no disclosed plan. A trading plan schedules sales in advance.

Are any Moderna insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

How much of their stake did Moderna insiders sell?

About 3.5% overall. As a group they ended with more shares than they started with. That covers the 12 months to Oct 8, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Stephane Bancel Chief Executive Officer, Director	$28.7M 499K shares	2.4%	Disclosed plan
Stephen Hoge President	$28.4M 401K shares	25%	Disclosed plan
James Mock Chief Financial Officer	$4.7M 35K shares	37%† i † Most of the shares James Mock sold arrived during the period, so this is shares sold as a share of the 18K held at the start plus the 130K received, less 53K withheld by the company for taxes.	Disclosed plan
Shannon Klinger Chief Legal Officer	$1.4M 21K shares	20%† i † Most of the shares Shannon Klinger sold arrived during the period, so this is shares sold as a share of the 28K held at the start plus the 124K received, less 50K withheld by the company for taxes.	Disclosed plan
Noubar Afeyan Director	$434K 9.3K shares	0.4%	No plan disclosed
Abbas Hussain Director	$279K 6.2K shares	34%† i † Most of the shares Abbas Hussain sold arrived during the period, so this is shares sold as a share of the 2K held at the start plus the 16K received, less 0 withheld by the company for taxes.	Disclosed plan

Board members representing outside shareholders, reported separately: Noubar Afeyan (the shareholder sold $703K). Details

The full ownership picture15 of 15 insiders fully reconciled · 13 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 8, 2025

Sold

Held Oct 8, 2026

Still held

Stephane Bancel

Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Chief Executive Officer, Director

21.27M

−499K

22.22M

+4.4%

Vesting, gifts, unvested awards and holding lines for Stephane Bancel

+1.44Mshares vested or exercised

0gifted (net of own trusts)

−5.5Kwithheld by the company for taxes

none reportedunvested awards, start → end

Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	5,493,897	6,440,260
Boston Biotech Ventures, LLC	Common Stock	9,210,686	9,210,686
OCHA LLC	Common Stock	6,564,880	6,564,880

Additional holdings last reported May 21, 2021, not confirmed since: 11,062 shares. Not included in any total or percentage on this page.

Unresolved (see footnote), Common Stock: 11,062 shares, last reported May 21, 2021

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
151,943	$96.20	Feb 27, 2034	$7.6M
357,065	$30.96	Mar 1, 2035	$41.1M
250,932	$53.57	Mar 1, 2036	$23.2M

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Noubar Afeyan

Minor difference of 3,924 shares. Difference is under 0.5% of holdings. Additional holdings last reported more than 3 years ago are shown separately and excluded from totals. Shares held through By: Flagship Venture Labs IV LLC, By: Flagship Ventures Fund IV, LP, By: Flagship Ventures Fund IV-Rx, LP and others belong to an outside shareholder this director represents; they are listed under "Board members representing outside shareholders", not here.

Director

2.22M

−9.3K

2.23M

+0.2%

Vesting, gifts, unvested awards and holding lines for Noubar Afeyan

+9.3Kshares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
Shares held through By: Flagship Venture Labs IV LLC, By: Flagship Ventures Fund IV, LP, By: Flagship Ventures Fund IV-Rx, LP and others belong to an outside shareholder this director represents; they are listed under "Board members representing outside shareholders", not here.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	2,224,015	2,224,015
Flagship Pioneering, LLC	Common Stock	0	3,924

Additional holdings last reported Aug 17, 2020, not confirmed since: 2,105,627 shares. Not included in any total or percentage on this page.

Except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, Common Stock: 2,101,703 shares, last reported Aug 17, 2020
Pioneering, Common Stock: 3,924 shares, last reported May 11, 2020

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,557	$122.13	May 6, 2034	$181K
25,512	$28.54	Apr 30, 2035	$3.0M
12,908	$48.79	May 6, 2036	$1.3M

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Reconciliation: minor difference of 3,924 shares. Difference is under 0.5% of holdings.

Stephen Hoge

President

1.61M

−401K

1.72M

+6.7%

Vesting, gifts, unvested awards and holding lines for Stephen Hoge

+538Kshares vested or exercised

0gifted (net of own trusts)

−34Kwithheld by the company for taxes

191K → 291Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	1,453,512	1,562,029
Trust	Common Stock	151,933	151,933
Valhalla, LLC	Common Stock	4,116	4,116

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
305,810	$12.21	Feb 23, 2027	$40.9M
43,894	$96.20	Feb 27, 2034	$2.2M
238,043	$30.96	Mar 1, 2035	$27.4M
125,466	$53.57	Mar 1, 2036	$11.6M

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Paul Sagan

Director

494K

no sales

Vesting, gifts, unvested awards and holding lines for Paul Sagan

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	703	703
By: The Paul Sagan Revocable Trust	Common Stock	312,027	312,027
By: The Chatham Trust	Common Stock	166,452	166,452
By: Erwin Park LLC	Common Stock	14,951	14,951

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,557	$122.13	May 6, 2034	$181K
25,512	$28.54	Apr 30, 2035	$3.0M

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Juan Andres

Started reporting during the period; starting holdings are from the Form 3. New Form 3 filed 2026-10-05; earlier filings set aside.

Chief Operating Officer

125K

no sales

Vesting, gifts, unvested awards and holding lines for Juan Andres

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Started reporting during the period; starting holdings are from the Form 3.
New Form 3 filed 2026-10-05; earlier filings set aside.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	125,000	125,000

Shannon Klinger

Chief Legal Officer

28K

−21K

81K

not meaningful

Vesting, gifts, unvested awards and holding lines for Shannon Klinger

+121Kshares vested or exercised

0gifted (net of own trusts)

−50Kwithheld by the company for taxes

257K → 383Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	28,170	81,340

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,635	$96.20	Feb 27, 2034	$1.2M
60,216	$96.20	Feb 27, 2034	$3.0M
34,716	$30.96	Mar 1, 2035	$4.0M
29,275	$53.57	Mar 1, 2036	$2.7M

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Francois Nader

Director

21K

33K

no sales

Vesting, gifts, unvested awards and holding lines for Francois Nader

+12Kshares vested or exercised

0gifted (net of own trusts)

12K → 4.2Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	20,607	32,781

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,557	$122.13	May 6, 2034	$181K
6,378	$28.54	Apr 30, 2035	$750K
6,454	$48.79	May 6, 2036	$628K

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

James Mock

Chief Financial Officer

18K

−35K

60K

not meaningful

Vesting, gifts, unvested awards and holding lines for James Mock

+127Kshares vested or exercised

0gifted (net of own trusts)

−53Kwithheld by the company for taxes

262K → 392Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	18,259	60,125

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,635	$96.20	Feb 27, 2034	$1.2M
60,216	$96.20	Feb 27, 2034	$3.0M
43,642	$30.96	Mar 1, 2035	$5.0M
37,639	$53.57	Mar 1, 2036	$3.5M

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Elizabeth Nabel

New Form 3 filed 2021-03-11; earlier filings set aside.

Director

3.1K

19K

no sales

Vesting, gifts, unvested awards and holding lines for Elizabeth Nabel

+16Kshares vested or exercised

0gifted (net of own trusts)

16K → 8.4Kunvested awards, start → end

New Form 3 filed 2021-03-11; earlier filings set aside.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	3,084	19,317

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,668	$122.13	May 6, 2034	$136K

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Sandra Horning

Director

2.4K

19K

no sales

Vesting, gifts, unvested awards and holding lines for Sandra Horning

+16Kshares vested or exercised

0gifted (net of own trusts)

16K → 2.1Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	2,352	18,585

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,668	$122.13	May 6, 2034	$136K
9,681	$48.79	May 6, 2036	$942K

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Abbas Hussain

Director

−6.2K

12K

not meaningful

Vesting, gifts, unvested awards and holding lines for Abbas Hussain

+16Kshares vested or exercised

0gifted (net of own trusts)

16K → 8.4Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	2,019	12,066

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,093	$63.16	Oct 2, 2034	$671K
5,100	$63.16	Oct 2, 2034	$423K

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

David Rubenstein

Director

1.5K

9.6K

no sales

Vesting, gifts, unvested awards and holding lines for David Rubenstein

+8.1Kshares vested or exercised

0gifted (net of own trusts)

8.1K → 2.1Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	1,527	9,643

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,051	$83.75	Aug 5, 2034	$315K
4,065	$83.75	Aug 5, 2034	$253K
12,756	$28.54	Apr 30, 2035	$1.5M
9,681	$48.79	May 6, 2036	$942K

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Elizabeth Tallett

Director

703

4.8K

no sales

Vesting, gifts, unvested awards and holding lines for Elizabeth Tallett

+4.1Kshares vested or exercised

0gifted (net of own trusts)

4.1K → 8.4Kunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock	703	4,761

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,557	$122.13	May 6, 2034	$181K
19,134	$28.54	Apr 30, 2035	$2.2M

Estimate: options held × ($146.07 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

15 of 15 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (14 exactly, 1 with a minor or footnoted difference). Percentages cover 10 of 15 officers and directors. Left out: Shannon Klinger, James Mock and Abbas Hussain (most of their shares vested during the period, so a percentage would mislead); Soria Banque and Michael McDonnell (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$63.9M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $63.9M across 970,950 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $63.5M · 99%

The lighter segment is sales with no plan disclosed in the filing ($434K), including tax-related sales outside a plan.

No plan disclosed · $434K

Sales with no 10b5-1 plan and no tax reference in the filing. $434K of it is Noubar Afeyan. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Noubar Afeyan, May 21, 2026

Taxes

$29.0M of sales (45.4%) cite tax obligations in their footnotes, $29.0M of them also under a plan. Separately, 142,664 shares ($8.0M) were withheld by the company for taxes, which isn't a market sale. Example: Stephane Bancel, Aug 5, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Stephane Bancel Chief Executive Officer, Director	499K	$28.7M	100%	45%	Aug 5, 2026 to Aug 5, 2026
Stephen Hoge President	401K	$28.4M	100%	44%	Feb 23, 2026 to Sep 15, 2026
James Mock Chief Financial Officer	35K	$4.7M	100%	7%	Sep 10, 2026 to Sep 10, 2026
Shannon Klinger Chief Legal Officer	21K	$1.4M	100%	2%	Mar 2, 2026 to Sep 1, 2026
Noubar Afeyan Director	9.3K	$434K	0%	0.7%	May 21, 2026 to May 21, 2026
Abbas Hussain Director	6.2K	$279K	100%	0.4%	Dec 9, 2025 to May 1, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$14K	$14K	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$7.8M	$7.8M	$0	$0
Mar 2026	$726K	$726K	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$3.3M	$2.8M	$0	$434K
Jun 2026	$2.9M	$2.9M	$0	$0
Jul 2026	$3.6M	$3.6M	$0	$0
Aug 2026	$28.7M	$28.7M	$0	$0
Sep 2026	$16.9M	$16.9M	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member

Held Oct 8, 2025

Sold

Held Oct 8, 2026

Still held

Noubar Afeyan

Most of this insider's holdings were last confirmed in 2022. Confirmed in the last three years: 14,294,263 shares. Not confirmed since: 130,898,298 shares, left out of this row. "Still held" is not shown because it would cover only the smaller, confirmed part.

Director

14.29M

−24K

14.29M

see note

Vesting, gifts, unvested awards and holding lines for Noubar Afeyan

+24Kshares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P	Common Stock	9,662,114	9,662,114
Flagship Ventures Fund IV, L.P	Common Stock	3,880,328	3,880,328
Flagship Ventures Fund IV-Rx, L.P	Common Stock	747,897	747,897
Flagship Pioneering, Inc	Common Stock	3,924	3,924

Additional holdings last reported May 13, 2022, not confirmed since: 130,898,298 shares. Not included in any total or percentage on this page.

Flagship Fund IV, Common Stock: 31,582,082 shares, last reported Dec 9, 2019
On May 11, 2020, Flagship Ventures Fund IV, L.P, Common Stock: 31,216,399 shares, last reported Dec 11, 2019
On August 17, 2020, Flagship Ventures Fund IV, L.P, Common Stock: 14,435,589 shares, last reported Aug 17, 2020
Flagship VentureLabs IV LLC and Flagship Pioneering, Inc, Common Stock: 11,464,359 shares, last reported May 13, 2022
By: Flagship Venture Labs IV LLC, Common Stock: 11,460,435 shares, last reported Apr 28, 2022
Flagship VentureLabs IV LLC, Common Stock: 11,460,435 shares, last reported Aug 17, 2020
Flagship Fund IV-Rx, Common Stock: 8,190,766 shares, last reported Dec 11, 2019
and Flagship Ventures Fund IV-Rx, L.P, Common Stock: 4,971,576 shares, last reported Aug 17, 2020
By: Flagship Ventures Fund IV, LP, Common Stock: 3,276,339 shares, last reported Apr 28, 2022
By: Flagship Ventures Fund IV-Rx, LP, Common Stock: 2,840,318 shares, last reported Apr 28, 2022

Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about half of the 5-year average. 6 insiders sold; the average is 6 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 8, 2026 Latest 12 months	971K	6	$63.9M
Oct 8, 2025 1 year earlier	4.7K	4	$197K
Oct 8, 2024 2 years earlier	551K	6	$62.9M
Oct 9, 2023 3 years earlier	3.67M	8	$562M
Oct 9, 2022 4 years earlier	3.46M	9	$605M
Oct 9, 2021 5 years earlier	3.14M	5	$606M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertaintyEvery officer and director reconciles

Every officer and director reconciles for this period.

Noubar Afeyan: minor difference of 3,924 shares. Difference is under 0.5% of holdings.

Inferred rename: "On December 9, 2019, Flagship Ventures Fund IV, L.P" is treated as the same holder as "Flagship Fund IV", because the old name was never reported again and the new one opened with the same balance (31,582,082 shares). Old name, new name

Inferred rename: "Flagship Fund IV" is treated as the same holder as "On May 11, 2020, Flagship Ventures Fund IV, L.P", because the old name was never reported again and the new one opened with the same balance (31,216,399 shares). Old name, new name

Inferred rename: "On May 11, 2020, Flagship Ventures Fund IV, L.P" is treated as the same holder as "Flagship Ventures Fund IV, L.P", because the old name was never reported again and the new one opened with the same balance (22,826,399 shares). Old name, new name

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,064 filings from SEC EDGAR, and how we read them

All 1,064 Forms 3, 4 and 5 filed for Moderna (SEC CIK 1682852) from Dec 7, 2018 to Oct 7, 2026, retrieved from SEC EDGAR on Oct 8, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (15)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Robert Langer	May 7, 2024	11,509,357 shares, last reported balance as of May 5, 2022
Stephen Berenson	May 7, 2024	22,203 shares, last reported balance as of May 3, 2024
Arpa Garay	Dec 7, 2023	3,690 shares, last reported balance as of Dec 6, 2023
Paul Burton	Nov 8, 2022	954 shares, last reported balance as of Nov 7, 2022
David Meline	Aug 11, 2022	2,857 shares, last reported balance as of Aug 10, 2022
Tal Zaks	Jul 2, 2021	No balance on record
Lori Henderson	May 28, 2021	901 shares, last reported balance as of May 27, 2021
Corinne Le Goff	Feb 2, 2021	No balance on record
Lorence Kim	Jun 4, 2020	1,202,510 shares, last reported balance as of Jun 2, 2020
Moncef Slaoui	Apr 30, 2020	No balance on record
Jennifer Lee	Mar 11, 2020	4,419 shares, last reported balance as of Mar 9, 2020
Peter Hutt	Nov 22, 2019	3,924 shares, last reported balance as of Nov 20, 2019
Israel Ruiz	Jun 28, 2019	4,559 shares, last reported balance as of Dec 11, 2018
John Mendlein	Dec 7, 2018	806,154 shares, last reported balance as of Dec 7, 2018
Jorge Gomez		No balance on record

Moderna insiders sold $63.9M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Outside holders, reported separately

Common questions

Is the Moderna CEO selling stock?

Why are Moderna insiders selling?

Are any Moderna insiders buying?

How much of their stake did Moderna insiders sell?

The evidence

No plan disclosed · $434K

Taxes

Sales by month